Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.